Values First Advisors Inc. Sells 3,885 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Values First Advisors Inc. lowered its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,840 shares of the company’s stock after selling 3,885 shares during the period. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $820,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MIRM. Lord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $28,913,000. Loomis Sayles & Co. L P acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $19,473,000. State Street Corp increased its stake in shares of Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after purchasing an additional 297,511 shares during the period. Erste Asset Management GmbH acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth about $10,136,000. Finally, Frazier Life Sciences Management L.P. boosted its stake in Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock valued at $256,245,000 after purchasing an additional 75,000 shares during the period.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $50.16 on Wednesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $53.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market cap of $2.41 billion, a P/E ratio of -24.83 and a beta of 0.96. The firm’s 50-day simple moving average is $44.97 and its 200-day simple moving average is $42.47.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.57) EPS. As a group, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MIRM has been the topic of several recent analyst reports. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners increased their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $57.10.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $85,554.36. Following the completion of the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,415 shares of company stock valued at $2,015,670 in the last 90 days. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.